Drugs / Autologous CCR4 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07055477 | Sep 2025 → Jun 2044 expected | anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma +4 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CCR4 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07055477 ↗ |
| Modality | Cell therapy | “Participants will undergo leukapheresis to obtain T-cells that will be genetically modified to express anti-CCR4 CARs on T-cells.” NCT07055477 ↗ |
| Route | Intravenous | “Day 0: Cells will be infused intravenously (IV) over 10-30 minutes” NCT07055477 ↗ |